- Home
- SNTI vs HNRA Comparison
SNTI vs HNRA Comparison
Compare SNTI & HNRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- HNRA
- Stock Information
- Founded
- SNTI 2016
- HNRA 2020
- Country
- SNTI United States
- HNRA United States
- Employees
- SNTI N/A
- HNRA N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- HNRA Oil & Gas Production
- Sector
- SNTI Health Care
- HNRA Energy
- Exchange
- SNTI Nasdaq
- HNRA Nasdaq
- Market Cap
- SNTI 15.6M
- HNRA 10.5M
- IPO Year
- SNTI N/A
- HNRA 2022
- Fundamental
- Price
- SNTI $2.87
- HNRA $1.36
- Analyst Decision
- SNTI
- HNRA Strong Buy
- Analyst Count
- SNTI 0
- HNRA 2
- Target Price
- SNTI N/A
- HNRA $6.75
- AVG Volume (30 Days)
- SNTI 38.4K
- HNRA 241.0K
- Earning Date
- SNTI 08-13-2024
- HNRA 01-01-0001
- Dividend Yield
- SNTI N/A
- HNRA N/A
- EPS Growth
- SNTI N/A
- HNRA N/A
- EPS
- SNTI N/A
- HNRA N/A
- Revenue
- SNTI $338,000.00
- HNRA $22,964,891.00
- Revenue This Year
- SNTI $254.47
- HNRA N/A
- Revenue Next Year
- SNTI $169.66
- HNRA N/A
- P/E Ratio
- SNTI N/A
- HNRA N/A
- Revenue Growth
- SNTI N/A
- HNRA N/A
- 52 Week Low
- SNTI $1.52
- HNRA $1.28
- 52 Week High
- SNTI $8.48
- HNRA $13.93
- Technical
- Relative Strength Index (RSI)
- SNTI 59.63
- HNRA 25.79
- Support Level
- SNTI $2.60
- HNRA $1.50
- Resistance Level
- SNTI $2.98
- HNRA $1.76
- Average True Range (ATR)
- SNTI 0.22
- HNRA 0.28
- MACD
- SNTI 0.06
- HNRA -0.08
- Stochastic Oscillator
- SNTI 88.17
- HNRA 7.19
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About HNRA HNR Acquisition Corp
HNR Acquisition Corp is a blank check company.